MDT

96.58

+0.2%↑

137.2

-0.16%↓

VEEV

223.32

0%↓

HQY

92.2

+0.26%↑

PHR.US

16.91

-0.24%↓

MDT

96.58

+0.2%↑

137.2

-0.16%↓

VEEV

223.32

0%↓

HQY

92.2

+0.26%↑

PHR.US

16.91

-0.24%↓

MDT

96.58

+0.2%↑

137.2

-0.16%↓

VEEV

223.32

0%↓

HQY

92.2

+0.26%↑

PHR.US

16.91

-0.24%↓

MDT

96.58

+0.2%↑

137.2

-0.16%↓

VEEV

223.32

0%↓

HQY

92.2

+0.26%↑

PHR.US

16.91

-0.24%↓

MDT

96.58

+0.2%↑

137.2

-0.16%↓

VEEV

223.32

0%↓

HQY

92.2

+0.26%↑

PHR.US

16.91

-0.24%↓

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.21 -1.63

Buy Sell

Overview

Share price change

24h

Current

Min

1.2

Max

1.24

Key metrics
By Trading Economics
Income	17M -26M
Profit margin	-2,190.837
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+143.9% upside

Market Stats
By TradingEconomics
Market Cap	-27M 76M
Previous open	2.84
Previous close	1.21

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

WiseTech to Sell Expedient to Appease Competition Regulator

30 gru 2025, 17:12 UTC

Major Market Movers

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 gru 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 gru 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 gru 2025, 20:37 UTC

Earnings

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 gru 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30 gru 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 16:20 UTC

Earnings

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 gru 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 gru 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 gru 2025, 15:10 UTC

Acquisitions, Mergers, Takeovers

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 gru 2025, 14:24 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 gru 2025, 14:22 UTC

Acquisitions, Mergers, Takeovers

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 gru 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 gru 2025, 14:17 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 gru 2025, 14:16 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 gru 2025, 14:14 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 gru 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

LVMH: Les Editions Croque Futur Is a French Publishing House

30 gru 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

LVMH Acquires Les Editions Croque Futur

30 gru 2025, 13:49 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 gru 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 gru 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 gru 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 gru 2025, 11:55 UTC

Market Talk

Earnings

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 gru 2025, 11:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 gru 2025, 11:35 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

143.9% upside

12 Months Forecast

Average 3 USD 143.9%

High 4 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.